View source version on businesswire.com: https://www.businesswire.com/news/home/20211109006417/en/, Strategic Decision Based Upon Recent Business Success and Plans to Support Continued Growth and Investments in OmniAb's Drug Discovery Platform, Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today announced it is pursuing plans to split Ligand into two separate, publicly traded companies with one featuring the OmniAb business, and the other featuring Ligand's existing collection of core royalties and the technologies, pipeline and contracts associated with the Pelican protein expression platform and the Captisol business. After significant planning and analysis, we have concluded we are operating two distinct, high-growth companies within Ligand. Ligand Pharmaceuticals is a biopharmaceutical company located in San Diego, California. The data for sugemalimab as a consolidation therapy demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS). Investors and security Under the terms of the merger agreement, Ligand will commence a tender offer to acquire all of the outstanding shares of Pfenex common stock for $12.00 per share, or $438 million upfront in cash. "Ligand stockholders will gain access to numerous royalty partnerships, additional pipeline assets, drug discovery resources and cash and NOLs. Eledon Pharmaceuticals is building upon a deep historical understanding of the CD40/CD40L pathway, as well as preclinical and Phase 1 data, to initiate up to four clinical studies in kidney transplantation, islet cell transplantation, IgA Nephropathy (IgAN), and amyotrophic lateral sclerosis (ALS). Investors and security holders Both companies It should be noted that when Grant's asked Ligand about these partners no response was given. PUNE, India, November 10, 2016 /PRNewswire/ --. "Our core royalties tied to Kyprolis and Evomela continue to grow nicely, and we have seen five approvals during the last year for new products or major markets that are now launching and are expected to fuel royalty growth next year and beyond. We are committed to running a company that has a broad TEMPE, Ariz.--(BUSINESS WIRE)--#biopharma--iMetabolic Biopharma Corporation (iMBP) announces expansion of its strategic partnership relationship with Ligand Pharmaceuticals, building on an earlier . Phase 1 top-line data met primary endpoint - July 10, 2019. discovery platform to sustain the growth of its development pipeline. Otherwise you will be prompted again when opening a new browser window or new a tab. If you refuse cookies we will remove all set cookies in our domain. Information about Pharmacopeia's executive officers and directors and Ligand disclaims any intent or obligation to update these forward-looking statements beyond the date of this release. "The iMetabolic pipeline molecules can be thought of, in essence, as gene therapy implemented purely at the protein level, and represent a strategy that we would be excited to see emerge as a clinically-viable modality," said Bill Harriman, Ph. On October 20, the Center for Disease Control's committee on immunization practices provisionally recommend vaccination either with a sequential regimen of VAXNEUVANCE followed by PNEUMOVAX23, or with a single dose of 20-valent pneumococcal conjugate vaccine for adults 65 years and older, and for adults ages 19 to 64 with certain underlying medical conditions or other disease risk factors. Actual events or results may differ from Ligand's expectations due to risks and uncertainties including, without limitation: there can be no assurance that the CRDC program with Ligand will be able to successfully confirm, discover or develop any desirable drug candidates or that any drug candidates developed in such program would be clinically successful, would receive necessary regulatory approvals, or would be commercially successful, all of which might result in the potential license option exercise fee, milestone payments and royalties not being earned; CRDC's drug candidates, if any, from this program might not proceed according to any intended timeline; results of any clinical study may not be timely, favorable or confirmed by later studies; effective COVID-19 vaccines and treatments may limit the market for this collaboration's intended drug products; Ligand or CRDC may not be able to protect their intellectual property and patents covering certain products and technologies may be challenged or invalidated; Ligand is dependent on CRDC for the development and, if approved, commercialization of drug products from the collaboration; CRDC may choose not to exercise the license agreement option, or may terminate or deprioritize development or commercialization of any drug candidates or products; Ligand may not be able to successfully implement its strategic growth plan and continue the development of its proprietary programs; and ongoing or future litigation could expose Ligand to significant liabilities and have a material adverse effect on the company. Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) announced today that John L. Higgins is joining the Company as Chief Executive Officer, President and a member of the Company's Board of Directors. On behalf of our Novartis Pipeline. Squibb, Celgene, Cephalon, GlaxoSmithKline, Schering-Plough and Wyeth Net income for the third quarter of 2021 was $13.7 million, or $0.80 per diluted share, compared with net loss of $(6.7) million, or $(0.42) per share, for the same period in 2020. DUBLIN, November 24, 2021--The "Diabetes - Pipeline Insight, 2021" clinical trials has been added to ResearchAndMarkets.com's offering. Aptevo Therapeutics announced positive Phase 1 data showing some patients with relapsed acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) achieved a remission with APVO436 after failing 1-8 lines of prior therapies. A Portfolio Diversified Across Partners, Indications, Technologies and Stage of Development. Read our Privacy Policy to learn more. . The spin-off is intended to create two companies with dedicated operational focus, business-specific capital allocation, agility to meet partner needs, and compelling focused investment profiles. Ligand Pharmaceuticals Incorporated "Ligand stockholders will gain access to an attractive partnership with Merck, additional pipeline assets and drug discovery . Latham & Watkins As part of the agreement, Fred Callori and Ben Askew, Ph.D., partners…. they have shown in pursuit of our scientific goals and the value they royalty partnerships, additional pipeline assets, drug discovery The Captisol® platform technology is a patent-protected, chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. The deal grants CRDC exclusive rights to use Ligand's BEPro technology for use in an oral COVID-19 antiviral […] You can check these in your browser security settings. Ligand is a revenue-generating biopharmaceutical company focused on developing or acquiring technologies that help pharmaceutical companies discover and develop medicines. indications including diabetic nephropathy, muscle wasting and Merck announced VAXNEUVANCE™ met key immunogenicity and safety endpoints in a Phase 3 pivotal trial evaluating use in infants. Securities and Exchange Commission (the "SEC"), including its recent Phase III clinical trials are being evaluated by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. for TQB 2450 for the renal cell carcinoma treatment. partnerships," Mr. Higgins continued. from the U.S. or (706) 679-0565 from outside the U.S. A replay of the During the third quarter, Ligand entered into an OmniAb licensing agreement with Pierre Fabre. Ligand's top-line revenues are set to grow by 16% in 2020, based on company forecasts, and the company has targeted adjusted EPS of $3.6, and a high EBIT margin of 50%. failure of Pharmacopeia's stockholders to approve the merger; Ligand in pharmaceutical science at North Dakota State University. Harbour BioMed licensed batoclimab from HanAll Biopharma and has the right to develop, manufacture and commercialize in Greater China (including Hong Kong, Macau and Taiwan). Dr. Cochran is the Shriram Chair of the Department of Bioengineering at Stanford University, where she also is a professor of bioengineering and (by courtesy) of chemical engineering and a member of the cancer biology, biophysics and immunology programs and was a Founder and former CEO of xCella Biosciences. Ent001 targets the TMEM219 ligand, IGFBP3, the levels of which are augmented in T1D and several other autoimmune diseases. CRDC's main business covers new drug research and development, preparations production, sales and marketing, pharmaceutical equipment, and API production. herein will be proven accurate. Net income for the nine months ended September 30, 2021 included a $2.4 million net non-cash gain from the value of Ligand's short-term investments, while net loss for the same period in 2020 included a net non-cash loss in the value of Ligand's short-term investments of $(17.9) million. The Company reports adjusted net income and adjusted net income per diluted share in addition to, and not as a substitute for, or superior to, financial measures calculated in accordance with GAAP. array of royalty assets and pipeline programs, backed by a strong Pipeline. Ent001 is the only drug in development with the potential to restore the endogenous pancreatic beta cells . from those in any forward-looking statements are the risk that the any forward-looking information is not a guarantee of future This is a unique Gastric adenocarcinoma or gastro-esophageal junction adenocarcinoma. pharmaceutical and biotechnology companies, including Bristol-Myers DelveInsight's "Renal Cell Carcinoma Pipeline Insight" report provides comprehensive insights about 80+ companies and 80+ pipeline drugs in the Renal Cell Carcinoma pipeline landscapes.It . timing of closing the merger, statements about the benefits of the call will be available until October 24, 2008 at 5:30 p.m. Eastern This press release does not constitute an offer to sell or the solicitation of an offer to buy securities, and shall not constitute an offer, solicitation, or sale in any jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction. here to unlock and sign up to a 14-day FREE TRIAL, Sermonix Pharmaceuticals Closes $40 Million Series A3 Financing Round Led by Perceptive Xontogeny Ventures Fund II, Ligand Reports Third Quarter 2021 Financial Results, https://www.businesswire.com/news/home/20211109006417/en/, Ligand Pursuing Plans for OmniAb to Become a Standalone Public Company, https://www.businesswire.com/news/home/20211109006386/en/, Ligand to Report Third Quarter Financial Results on November 9, 2021, https://www.businesswire.com/news/home/20211026006038/en/, Ligand and CR Double-Crane Enter Collaboration Agreement to Develop an Oral COVID-19 Therapeutic Using Ligand's BEPro Technology™, https://www.businesswire.com/news/home/20211021005381/en/, View All Phase 2 part B data noted when administered by hand-held pMDI over one week treatment provided clinically meaningful, statistically significant and dose-dependent bronchodilation, noted October 13, 2021. To participate via live or replay webcast, a link is available at www.ligand.com. "We believe more than ever that OmniAb offers one of the industry's leading antibody discovery platforms and that the business is primed for success for years to come. Ensifentrine (RPL554) - Metered Dose Inhaler. He completed a visiting research fellowship at Brigham and Women’s Hospital. The business has 83,000 square feet of state-of-the-art Research & Development and cGMP manufacturing facility in Round Rock, Texas. Live and replay webcast of the call are available here. She was most recently Chief Commercial Officer at resTORbio™, and previously served as Vice President of Global Product Strategy in Hemophilia for Shire (formerly Baxalta) and Baxter. Unique asset for use in multiple solid tumors; Advancing leading candidate. . at Colorado College and an MBA from the University of Chicago Booth School of Business. Ligand disclaims any intent or obligation to update these forward-looking statements beyond the date of this release, including the possibility of additional contract revenue we may receive. CStone also presented updated data from the registrational study of sugemalimab in patients with stage IV NSCLC in an oral presentation at the IASLC 2021 World Conference on Lung Cancer. Meredith Manning joined PharmaEssentia as General Manager for the U.S. in 2020, bringing with her more than 20 years of experience in global commercialization and brand building for biopharmaceuticals and medical devices. The PXV Fund team brings significant scientific, business, operational and investment expertise to the Sermonix team, with a singular goal of shepherding lasofoxifene through compelling and rigorously designed clinical proof-of-concept studies. "This is a pivotal moment for Sermonix. PharmaEssentia’s clinical pipeline reflects our hematology/oncology focus, with candidates across a range of indications in development around the world. Topline data are also expected in the first half of 2022. their ownership of Pharmacopeia common stock is set forth in the proxy BEPro is a proprietary prodrug technology that is specifically applicable to nucleotides and nucleotide…. As of September 30, 2021, Ligand had cash, cash equivalents and short-term investments of $323.2 million. transaction between Ligand and Pharmacopeia, including future Partners seek the platform as it can contribute significant value to biopharmaceutical development programs by reducing development timelines and costs for manufacturing therapeutics and vaccines. Pharmacopeia by going to Pharmacopeia's Investor Relations page on its Other operating income was $37.6 million for the nine months ended September 30, 2021, which represented a non-cash valuation adjustment related to eliminating the Pfenex CVR liability. We partner with other pharmaceutical companies to leverage what they do best (late-stage development, regulatory management and commercialization) ultimately to generate our revenue. Travere met with the FDA for sparsentan in focal segmental glomerulosclerosis (FSGS) confirming plans to submit additional data in the first half of 2022 as part of an accelerated approval submission. The company is leveraging its fully integrated drug opportunities to create value for our shareholders. "We are excited to welcome investors who share our passion as we work to leverage a precision medicine approach to address a significant unmet need in the metastatic breast cancer setting," said David Portman, M.D., Sermonix founder and chief executive officer. development programs, strengthen our research capability and increase The failure to meet expectations with respect to any of the foregoing matters may reduce Ligand's stock price. This news release contains forward-looking statements by Ligand that involve risks and uncertainties and reflect Ligand's judgment as of the date of this release. © 2021 PharmaEssentia Corporation. Our co-lead clinical development candidates are KP415 - a prodrug product of . Elizabeth Attias, M.M.Sc., Sc.D., chief strategy and development officer, has extensive experience in pharmaceutical drug commercialization. Ligand Pharmaceuticals wants another piece of the COVID-19 pie. Primary investments for the venture funds include companies that are seeking a lead investor for Series A financings, which include both companies that are seeded and operationally supported by Xontogeny LLC, an affiliated biotech accelerator, as well as unaffiliated companies that are seeking direct Series A investments. Because these cookies are strictly necessary to deliver the website, refuseing them will have impact how our site functions. Ligand's goal is to produce a bottom line that supports a sustainably profitable business. Mr. Higgins provided the following strategic and operating and other statements that are not historical facts. You are free to opt out any time or opt in for other cookies to get a better experience. other documents filed by Ligand or Pharmacopeia with the SEC, may be company will have important product introductions. Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) will report financial results for the three and nine months ended September 30, 2021 after the close of the U.S. financial markets on Tuesday, November 9, 2021 and will hold a conference call that same day beginning at 4:30 p.m. Eastern time. Our Pipeline :: Aurinia Pharmaceuticals Inc. (AUPH) Our Pipeline. Cost of goods sold was $50.2 million for the nine months ended September 30, 2021, compared with $18.7 million for the same period in 2020, with the increase primarily attributable to higher sales of Captisol. We may request cookies to be set on your device. to achieve considerable cost savings by consolidating certain "We are very excited about combining Pharmacopeia with Ligand," Pipeline. (3) Amounts represent changes in fair value of contingent consideration related to Pfenex, Icagen, Crystal, CyDex, and Metabasis transactions. may obtain free copies of the documents filed with the SEC by Words such as "plans," "believes," "expects," "anticipates," and "will," and similar expressions, are intended to identify forward-looking statements. "We believe lasofoxifene, if approved, may become a treatment of choice for oncologists and many of their patients with this challenging disease. deemed to be participants in the solicitation of proxies from the This news release contains forward-looking statements by Ligand that involve risks and uncertainties and reflect Ligand's judgment as of the date of this release. relationships with collaborators, partners, employees or suppliers; balance sheet and staunch spending discipline. Ligand has filed multiple patents globally on the BEPro technology and potential antiviral compounds. This unique technology has enabled several FDA-approved products, including Gilead's VEKLURY®, Amgen's KYPROLIS®, Baxter International's NEXTERONE®, Acrotech Biopharma L.L.C. Ligand has assembled one of the largest portfolios of biopharmaceutical assets among our peers which provides investors the opportunity to participate in the promise of the biotech industry in a profitable, diversified and lower-risk business than a typical biotech company. and M.S. addition, investors and security holders may obtain free copies of the This study aims to assess the efficacy and safety of batoclimab in patients with gMG in China. The failure to meet expectations with respect to any of the foregoing matters may reduce Ligand's stock price. General and administrative expense was $12.7 million for the third quarter of 2021, compared with $15.0 million for the same period in 2020, with the decrease primarily due to $4.9 million of acquisition and integration costs in the prior-year period. Ligand's Pelican Expression Technology™ is a robust, validated, cost-effective and scalable approach to recombinant protein production, and is especially well-suited for complex, large-scale protein production that cannot be made by traditional systems. Ligand.". voting or investment decision with respect to the proposed Individual investors Management has excluded the effects of these items in its adjusted measures to assist investors in analyzing and assessing the Company's past and future core operating performance. In 10 stocks we like better than Ligand Pharmaceuticals When o ur award-winning analyst team has a stock . Total revenues for the nine months ended September 30, 2021 were $204.7 million, compared with $116.4 million for the same period in 2020. KemPharm offers exciting and rewarding career opportunities in the biotechnology area as part of a dynamic and culturally diverse team. This report provides comprehensive insights about 200+ companies and 200+ pipeline drugs in Diabetes pipeline landscape. D., Senior Vice President of Antibody Discovery at Ligand Pharmaceuticals. New drug applications for sugemalimab in patients with metastatic stage IV NSCLC and in patients with locally advanced/unresectable stage III NSCLC have been accepted by China's NMPA and are currently under review. At Biogen, he did innovative research and made discoveries related to cytokines, immunology, and gene therapy. It is the second most common neurodegenerative disease, with an estimated 10 million patients with PD worldwide in 2020. This represents a 57% premium to the closing price of Pfenex's stock on August 10, 2020. Earlier in his career, he held clinical development and R&D roles at Pfizer, Bayer and Biogen®. About Ligand Pharmaceuticals Ligand is a revenue-generating biopharmaceutical company focused on developing or acquiring technologies that help pharmaceutical companies discover and develop medicines. Ligand's business model is based on doing what Ligand does best: drug discovery, early-stage drug development, product reformulation and partnering. Changes will take effect once you reload the page. Due to security reasons we are not able to show or modify cookies from other domains. Royalties for the third quarter of 2021 were $15.6 million, compared with $9.0 million for the same period in 2020. The accomplished team at Sermonix recognizes the acute medical need and will be executing effectively on these strategies.". The spin-off is intended to create two companies with dedicated operational focus, business-specific capital allocation, agility to meet partner needs, and compelling…. unmet medical needs of patients with thrombocytopenia, hepatitis C, Ligand's goal is to offer investors an opportunity to participate in the promise of the biotech industry in a profitable, diversified and lower-risk business than a typical biotech company. The versatility of the platform has been demonstrated in the production of enzymes, peptides, antibody derivatives and engineered non-natural proteins. have created for our shareholders. Senior Group Leader at Array BioPharma®, and earlier as a research scientist at Amgen® and Ligand® Pharmaceuticals. Ligand Pharmaceuticals LGND stock has gained 62.2% so far this year against 17.3% decrease of the industry. Other trademarks and copyrights appearing in this press release are the property of their respective owners. The following cookies are also needed - You can choose if you want to allow them: You can read about our cookies and privacy settings in detail on our Privacy Policy Page. SAN DIEGO, CA, USA I September 9, 2014 I Ligand Pharmaceuticals Incorporated announced it has expanded its global license agreement with CURx Pharmaceuticals, Inc. to also include the development and commercialization of Ligand's Captisol-enabled™ Lamotrigine program. opportunity for Ligand and Pharmacopeia shareholders. Earlier in his career, he contributed to inventions in HIV in his research roles at Monsanto. Goldman Sachs acted as financial advisor to Ligand and Cowen and statement regarding the merger, which will be filed with the SEC. documents filed with the SEC by Ligand by going to Ligand's Investor Jazz Pharmaceuticals announced the National Comprehensive Cancer Network added Rylaze™ to its Clinical Practice Guidelines in Oncology as a treatment option for both pediatric and adult acute lymphoblastic leukemia patients with hypersensitivity to E. coli asparaginase products as a component of the multi-agent chemotherapeutic regimen. Words such as "plans," "believes," "expects," "anticipates," and "will," and similar expressions, are intended to identify forward-looking statements. For more information, please visit www.ligand.com. said John L. Higgins, President and Chief Executive Officer of Ligand The Company's financial measures under GAAP include share-based compensation expense, amortization of debt-related costs, amortization related to acquisitions and intangible assets, changes in contingent liabilities, mark-to-market adjustments for amounts relating to its equity investments in public companies, excess tax benefit from share-based compensation and others that are listed in the itemized reconciliations between GAAP and adjusted financial measures included at the end of this press release. Under the terms of the expanded license, Ligand will be eligible to receive $22 million in potential milestone payments . affect future results are detailed in Ligand's filings with the Lasofoxifene is also being studied in a separate fully-enrolled trial, ELAINE 2, in combination with Eli Lilly and Company's CDK4 and 6 inhibitor Verzenio® (abemaciclib). The latest corporate presentation can be accessed at investor.ligand.com. products, or that any of the forward-looking information provided Our business model creates value for stockholders by providing a diversified portfolio of biotech and pharmaceutical product revenue streams that are supported by an efficient and low corporate cost structure. Additional important factors that may Click, Ensifentrine (RPL554) - (ENHANCE-1 and ENHANCE-2), Chronic obstructive pulmonary disease (COPD), Non-alcoholic steatohepatitis (NASH) and fibrosis. Benefitting from our continued focus on innovation, Novartis has one of the industry's most competitive pipelines with more than 150 projects in clinical development. Existing investors also participated in the financing. other relevant materials in connection with the proposed transaction. liquidity. All rights reserved. As part of the agreement, Fred Callori and Ben Askew, Ph.D., partners in the PXV Fund, were appointed to the Sermonix Board of Directors. Ligand will receive an upfront payment in respect of the collaboration, and if the program advances, clinical and regulatory milestone payments, and tiered royalties on net sales. stockholders of Pharmacopeia in favor of the proposed transaction. Phase 2 negative data released July 23, 2019. developed or manufactured, that final results of clinical studies will DUBLIN, September 28, 2021--(BUSINESS WIRE)--The "Chronic Lymphocytic Leukemia - Pipeline Insight, 2021" clinical trials has been added to ResearchAndMarkets.com's offering.. Please be aware that this might heavily reduce the functionality and appearance of our site. Moderate-to-severe TED is characterized by swelling and redness of the eyelids, proptosis (protrusion of the eyeball), double vision, and, in severe cases, corneal ulceration and decreased visual acuity. Under the deal, Ligand Pharmaceuticals will purchase all outstanding shares of Pfenex for $12 per share in cash or $438m in equity value on a fully diluted basis. Icagen Ion Channel Technology's Dr. Anil Nair presented at the 3rd Annual Drug Discovery & Development Summit and gave an oral presentation entitled "In Silico Drug Discovery: Application of Computer-Aided Drug Design in an Industrial Environment". Ligand's Pelican Expression Technology™ is a robust, validated, cost-effective and scalable approach to recombinant protein production, and is especially well-suited for complex, large-scale protein production that cannot be made by traditional systems. "Ligand stockholders will gain access to numerous Ligand owns or has rights to trademarks and copyrights that it uses in connection with the operation of its business including its corporate name, logos and websites. Cost of Captisol was $11.4 million for the third quarter of 2021, compared with $6.4 million for the same period in 2020, with the increase primarily due to higher sales of Captisol. Ligand has established multiple alliances, licenses and other business relationships with the world's leading pharmaceutical companies including Amgen, Merck, Pfizer, Roche, Jazz Pharmaceuticals, Sanofi, Janssen, Takeda, Gilead Sciences, GSK and Baxter International. Pharmacopeia's shareholders will receive a substantial amount of equity in a well capitalized company with lucrative potential royalties, an expanded pipeline and financial liquidity. As of September 30, 2021, 19 different OmniAb-derived antibodies have been studied in approximately 84 active or completed clinical trials. This Chronic lymphocytic leukemia - Pipeline Insight, 2021 report provides comprehensive insights about 60+ companies and 60+ pipeline drugs in Chronic lymphocytic leukemia pipeline landscape. Sermonix expects data from the trial to be reported in the first half of 2022. Investors and security holders of Pharmacopeia are urged For more information, please visit www.ligand.com. The CVRs will entitle holders under certain (5) Amounts primarily relate to loss on debt extinguishment. Ligand's OmniAb® technology platform is a patent-protected technology stack used in the discovery of fully human mono- and bispecific therapeutic antibodies. "We are pleased to announce our support for Sermonix Pharmaceuticals in their endeavors to develop an effective treatment for the approximately 40% of breast cancer patients who develop ESR1 mutations and progress following endocrine therapy," said Mr. Callori. Products & Possibilities. Phase 3 trial has been initiated by partner CStone Pharmaceuticals. impressive partnership roster of leading pharmaceutical companies, Captisol sales were $128.9 million for the nine months ended September 30, 2021, compared with $69.0 million for the same period in 2020, with the increase primarily due to higher sales of Captisol for use with remdesivir. our potential royalty streams. OmniAb animals comprise the most diverse host systems available in the industry and they are optimally leveraged through computational antigen design and immunization methods, paired with high-throughput microfluidic-based single B cell screening and deep computational analysis of next-generation sequencing datasets to identify fully human antibodies with superior performance and developability characteristics.
Green Dot Stables East Lansing,
Kotlin Linkedhashmap Example,
Ffxiv Easy Achievement Certificates,
Psac Volleyball Records,
Dentaquest Find A Dentist,
Hank Madness Combat Plush,
Wredling Middle School Bell Schedule,